Clinical Trials Logo

Immunomodulation clinical trials

View clinical trials related to Immunomodulation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06218225 Completed - Immunomodulation Clinical Trials

Effect of an Immune-boosting Food Supplement on the Severity and Frequency of Pediatric Respiratory Tract Infections

Start date: October 15, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy of the product in developing immune reinforcement that results in decreased susceptibility to respiratory infections of viral origin in children aged 3 to 10 years with a number of respiratory tract infectious events in the previous year greater than 4. The main questions it aims to answer are: - Has the number of infectious events been reduced from last year? - Does the severity of symptoms decrease with the use of the product? Participants will be treated for 4 months. Treatment efficacy will be evaluated by: - 2 scheduled visits with the investigating pediatrician (T0 - enrollment and start of treatment; T1- end of treatment). - Verification of progress during the study by scheduled telephone meetings. - The use of a diary where the patient or parent/caregiver will report all events (even mild) affecting the respiratory tract, taking care to fully complete the Wisconsin Upper Respiratory Symptom Survey for kids (WURSS-k) questionnaire.

NCT ID: NCT05222347 Completed - Immunomodulation Clinical Trials

Immunomodulatory and Preventive Effects of Olive Leaf Tea Against COVID-19

Start date: September 1, 2020
Phase:
Study type: Observational

During the Coronavirus Disease-2019 (COVID-19) pandemic, in addition to the current measures, boosting the immune system seems to be one of preventive measures that can be taken against COVID-19 infection. Various natural agents have been recommended to boost the immune system. The aim of this study was to investigate the possible immunomodulatory and preventive effects of Olive Leaf Tea (OLT) drinking with regards to COVID-19 infection. The study was conducted among 249 workers in a tractor factory where OLT was served. Of the 249 workers, 168 of them were OLT drinkers and 81 were not OLT drinkers. Drinking at least one cup of OLT per day for a minimum of one month was the inclusion criteria used in the study. The workers with a history of infection or vaccination of COVID-19 were excluded. Lymphocyte subsets, IL2, INF-gamma, specific IgM, and IgG levels were analyzed in all the study subjects. The results showed higher values of CD3-/CD16/56 (NK) cells, CD3+/CD16/56 (NKT) cells, total NK (NK+NKT) cells, and serum IFN-gamma and IL-2 levels in OLT drinkers as compared to the nondrinkers. These immune changes are indicative of immune defense mechanisms. Although all the OLT drinkers and non-drinkers reported no history of COVID-19, specific COVID-19 IgG levels were found positive in 60% of OLT drinkers and 38% OLT non-drinkers. There were significant negative correlations between age and NK cells, number of cigarettes smoked and NK cells, number of cigarettes smoked and TNK; and there were positive correlations between OLT drinking frequency and TNF-alpha, IL-2 and IFN-gamma. Also, serum creatinine levels in OLT non-drinkers were found significantly higher than in the OLT drinkers. In conclusion, drinking OLT may contribute fighting against COVID-19 by boosting the innate immune system.

NCT ID: NCT03107663 Completed - Hodgkin Lymphoma Clinical Trials

⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma

Start date: June 19, 2017
Phase: Phase 1
Study type: Interventional

To determine the safety and feasibility of 89Zr-Df-IAB22M2C as an immunoPET tracer; determine the best time window and protein dose for imaging; determine the pharmacokinetic (PK) and biodistribution of the probe; and to determine imaging parameters for optimal lymphoid and tumor visualization.

NCT ID: NCT01736696 Completed - Psoriasis Clinical Trials

Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis

Start date: November 2002
Phase: Phase 1
Study type: Interventional

This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics. This subject population was selected to evaluate potentially relevant biological activity of CP-690,550 as well as assessing safety and pharmacokinetics.